NON-SMALL-CELL LUNG CANCER

This trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…

This phase 2 trial is testing whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. The study includes 142 participants whose tumors are considered removable or…

This phase 3 trial tests whether a daily inhaler containing two bronchodilators (vilanterol and umeclidinium) can help preserve lung function and improve quality of life in people with mild-to-moderate COPD who are undergoing lung cancer surgery. About 204 participants will use t…

This phase II trial investigates whether adding two immunotherapy drugs—tiragolumab and atezolizumab—to standard chemotherapy before and after surgery can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls 35 adults with stage II to IIIB dis…

This Phase 3 trial compares a new oral drug, JDQ443, to the standard chemotherapy docetaxel in about 95 people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. Participants have already tried platinum-based chemo and an immunotherapy drug. The stud…

This study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …

This phase 2 trial tests whether combining sacituzumab govitecan (a targeted antibody-drug conjugate) with pembrolizumab (an immunotherapy) before and after surgery can improve outcomes for people with resectable non-small cell lung cancer (NSCLC). Participants receive four cycle…

This Phase III trial tests whether adding oleclumab or monalizumab to the standard drug durvalumab can help people with stage III non-small cell lung cancer that hasn't worsened after chemoradiation. About 1,050 participants will receive one of the combinations or a placebo. The …

This phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …

This study tests an experimental drug called CLN-081 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already received chemotherapy. The goal is to see if the drug is safe and can shrink tumors.

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase II trial tests whether adding canakinumab, an anti-inflammatory drug, to standard chemoradiation and immunotherapy (durvalumab) helps control locally advanced non-small cell lung cancer. About 41 participants will receive the combination to see if it improves progressi…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This phase 3 trial tests an experimental drug called SY-5007 in people with advanced non-small cell lung cancer that has a specific genetic change (RET fusion). The drug is a daily pill designed to block the cancer-driving RET protein. The study aims to see how well the drug shri…

This early-stage trial tests a new daily pill, zongertinib, in adults with advanced cancers that have HER2 gene changes, including non-small cell lung cancer. The first part finds the safest dose; the second checks if it shrinks tumors. Participants stay on the drug as long as it…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This phase 3 trial tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive non-small cell lung cancer). About 412 participants will receive either the combination or a placebo plus osim…

This study tests a new drug called JDQ443 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and does not respond well to standard treatments. The drug is taken as a pill and aims to shrink or control the cancer. About 95 participants will…

This trial is testing a combination of the immunotherapy drug tislelizumab plus two chemotherapy drugs (albumin-bound paclitaxel and a platinum agent) in 30 people with a specific type of lung cancer called KRAS-mutant non-small cell lung cancer. The participants have advanced or…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This study tests a new treatment plan for people with advanced non-small cell lung cancer that cannot be removed by surgery. Participants first receive chemotherapy plus immunotherapy, then radiation with more chemo, followed by additional immunotherapy. The goal is to see if thi…

This pilot study tests a combination of three drugs—zimberelimab, domvanalimab, and etrumadenant—in 30 adults with advanced non-small cell lung cancer who have already been treated with immunotherapy. The goal is to see if the triple therapy is safe and can shrink tumors. The stu…

This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…

This study tests whether two immunotherapy drugs, balstilimab and botensilimab, are safe and effective as a first treatment for people with metastatic non-small cell lung cancer. The trial includes 45 participants who have not had prior treatment for advanced disease. Researchers…

This phase 3 trial tests whether giving the targeted drug osimertinib (Tagrisso) before surgery, alone or with chemotherapy, works better than standard chemotherapy alone for people with a specific type of lung cancer (EGFR-mutant, non-small cell). About 358 patients with stage I…

This early-stage trial tests a new drug called amivantamab in people with advanced non-small cell lung cancer. The drug is a special antibody that targets two proteins on cancer cells. Researchers are checking safety and how well it works, both alone and with other treatments. Ab…

This large study is testing several targeted therapies and immunotherapies for people with advanced non-small cell lung cancer. Instead of a tissue biopsy, a simple blood test is used to find specific genetic changes in the cancer. The goal is to see if matching the right drug to…

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

This study looks at how well a combination of two immunotherapy drugs (nivolumab and ipilimumab), with or without chemotherapy, works as a first treatment for advanced or recurrent non-small cell lung cancer in Japan. Researchers will track about 525 patients to measure survival,…

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The study includes 169 participants and aims to see if t…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps control stage III lung cancer that cannot be removed by surgery. About 76 adults with a specific EGFR gene mutation will receive the drug as induction therapy, then contin…

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…

This early-stage trial tests a new drug called HLX43, an antibody-drug conjugate that targets PD-L1, in people with advanced or metastatic solid tumors that have not responded to standard treatments. Participants also receive another immunotherapy drug, serplulimab (HLX10). The m…

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This early-stage trial is testing a new drug called anvumetostat, alone or with other cancer drugs, in about 49 adults with advanced lung or chest tumors that lack a gene called MTAP. The main goals are to find the safest dose and to see what side effects occur. Researchers will …

This study tests a new drug, Tuvusertib, combined with an immunotherapy called Cemiplimab in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has worsened after prior treatments. The trial aims to see if the combination can shrink tumors and …

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This phase 2 study tests whether combining two targeted drugs, osimertinib and selumetinib, can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer who have not yet received EGFR inhibitors. The trial enrolls 25 participants and measures how well the tumo…

This phase 3 trial tests a new oral drug called sunvozertinib (DZD9008) against standard chemotherapy in 324 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon20 insertion). Participants are randomly assigned to receive either the new drug or …

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This study tests whether eating 3-6 servings of fermented foods daily (like yogurt, kefir, and sauerkraut) can improve how well cancer treatments work in patients with locally advanced rectal cancer or non-small cell lung cancer. The 39 participants are randomly assigned to eithe…

This phase 2 trial is testing a combination of two drugs—nivolumab and ramucirumab—in 36 people with advanced non-small cell lung cancer that has returned or spread. Participants have already had immunotherapy. The goal is to see if the combo can control the disease by boosting t…

This study tests whether adding two new drugs (datopotamab deruxtecan and rilvegostomig) after surgery can help prevent early-stage lung cancer from coming back. It is for people with stage I adenocarcinoma non-small cell lung cancer who have signs of cancer DNA in their blood or…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study tests whether the immunotherapy drug nivolumab, alone or with chemotherapy, can shrink early-stage non-small cell lung cancer before surgery and help prevent it from coming back after surgery. About 316 people with stage II or IIIA lung cancer that can be removed will …

This study tests an oral drug called mobocertinib in Japanese adults with non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 53 people will take the drug daily for up to a year or longer if their cancer s…

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a specific genetic change called MET alteration. About 47 adults in China with non-small cell lung cancer that has spread will receive the c…

This phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable …

This study tests two different schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy. It includes 76 adults with advanced or recurrent non-small cell lung cancer who have not had prior tr…

This study tests whether the targeted drug osimertinib can help prevent lung cancer from returning after surgery in patients with uncommon EGFR gene mutations. About 51 adults with stage IB-IIIB non-small cell lung cancer will take an 80 mg pill daily for up to 3 years. Researche…

This early-stage trial tests a new drug called YL202 in about 80 people with advanced lung or breast cancer that has not responded to standard treatments. The drug is given by IV every three weeks. The main goal is to check safety and find the right dose, not yet to prove it work…

This study compares a new drug, tobemstomig, combined with chemotherapy against the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if the new combination works better a…

This early-phase study tests whether combining two cancer drugs—ceritinib and docetaxel—can safely help people with advanced non-small cell lung cancer that has not responded to other treatments. About 21 adults with stage IIIB or IV disease will receive the drugs to find the bes…

This early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study tests whether adding the drug durvalumab to targeted radiation (SBRT) can help keep early-stage non-small cell lung cancer from coming back. It included 13 people with stage I to IIIA disease. The main goal was to see how long they lived without their cancer getting wo…

This study tests whether combining two targeted drugs, alectinib and cobimetinib, can safely treat advanced ALK-positive non-small cell lung cancer. Researchers will first find the best dose with acceptable side effects, then measure how often tumors shrink. The trial enrolls 16 …

This study tests whether adding the experimental drug SKB264 to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 406 participants who have not had …

This early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…

This phase 2 trial tests the safety and effectiveness of SKB264, a new drug, in 321 adults with advanced solid tumors, specifically non-small cell lung cancer and nasopharyngeal carcinoma. Participants receive SKB264 alone until the drug stops working or side effects become too s…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This phase 3 trial compares a new targeted drug, sacituzumab govitecan, against the standard chemotherapy docetaxel in 603 people with advanced non-small cell lung cancer that has worsened after prior treatments. The main goal is to see if the new drug helps people live longer. T…

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy in 376 adults with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to targeted therapy. The goal is to see if SKB264 can slow cancer growth better than chemo. …

This phase 2 trial is testing whether combining two drugs, ensartinib and bevacizumab, can help people with advanced lung cancer that has both an ALK rearrangement and a TP53 mutation. The study includes 47 participants who take ensartinib daily and receive bevacizumab every thre…

This Phase III trial tests whether adding immunotherapy to standard chemotherapy after lung cancer surgery can delay or prevent the cancer from coming back. It enrolls 210 patients with stage IB-IIIA non-small cell lung cancer that was completely removed. Participants are randoml…

This study tests whether a single, powerful dose of targeted radiation (SBRT) can safely control central non-small cell lung cancer, instead of the usual multiple sessions. About 30 adults with early-stage tumors near the chest center will receive one treatment. Researchers will …

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long …

This phase II trial tests whether adding stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy improves survival for people with non-small cell lung cancer that has spread to only a few spots (oligometastatic). About 140 participants are randomly assigned to r…

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …

This phase 2 study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese patients with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the drugs can shrink tumors and control the disease. About 63 pat…

This phase II trial tests whether adding immunotherapy to standard chemotherapy before surgery helps eliminate more lung cancer in patients with advanced, but potentially removable, non-small cell lung cancer. 90 participants will be randomly assigned to receive either chemo-immu…

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This phase 3 study tests whether the immune-boosting drug atezolizumab can delay or prevent lung cancer from coming back in patients who have already had surgery and chemotherapy. About 1,280 people with stage IB to IIIA non-small cell lung cancer are taking part. Half receive at…

This early-phase trial is testing a new drug called IMA401, which helps the body's immune T cells attack cancer cells that have certain markers (MAGE-A4 or MAGE-A8). The study includes about 95 adults with advanced solid tumors that have come back or not responded to other treatm…

This early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can…

This study tested a drug called sacituzumab govitecan in 227 people whose solid tumors had spread to other parts of the body. The main goal was to see if the drug could shrink tumors. Researchers measured how many patients had their tumors shrink or disappear. This is not a cure,…

This study aimed to compare three different immunotherapy drug regimens given before and after surgery for people with early-stage non-small-cell lung cancer. The goal was to see which approach best prevented the cancer from coming back. However, the trial was withdrawn before en…

This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and feasible for people with advanced EGFR-mutant non-small cell lung cancer who have not taken similar drugs before. About 48 participants will receive the combination for up to 6 months. R…

This study tests a two-step treatment for people with a specific type of lung cancer (EGFR-mutant, stage II-IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, they have su…

This early-phase trial tests two drugs, tepotinib and pembrolizumab, together in 19 people with advanced non-small cell lung cancer. Tepotinib targets a specific gene change (MET) that can help cancer grow, while pembrolizumab boosts the immune system. The goal is to see if this …

This study tests a new drug called PLB1004 against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 327 adults with this cancer type will be randomly assigned to receive either PLB1004 or …

This Phase 3 trial tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after initial osimertinib treatment. About 98 participants will receive either osimerti…

This phase 3 trial tests whether the targeted drug osimertinib (Tagrisso) can prevent lung cancer from returning in patients with early-stage (IA2-IA3) non-small cell lung cancer that has a specific EGFR mutation. About 390 participants who have had complete tumor removal surgery…

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 432 people with advanced non-small cell lung cancer whose previous targeted therapy (EGFR-TKI) has stopped working. The study compares how long the cancer stays under control and overall survival…

This Phase 3 trial compares a new drug called BL-B01D1 to the standard chemo docetaxel in 698 people with advanced non-small cell lung cancer that has not responded to prior immunotherapy and chemo. The goal is to see if BL-B01D1 helps people live longer. Participants receive eit…

This phase 2 trial tests whether adding ramucirumab to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their disease worsening. About 160 patients will receive either the combination or osimertinib alone. The study aims to see …

This phase 2 study tests an experimental drug called zelenectide pevedotin in 73 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (NECTIN4 amplification) and has already been treated with at least one prior therapy. The drug is give…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This study tests a three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with lung cancer that has worsened after initial treatment. The goal is to find the safest dose and see if the combination can shrink tumors or slow disease progression. About 31 particip…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This early-phase study tests whether combining two drugs—sarilumab (Kevzara) and cemiplimab—can safely control non-small cell lung cancer with specific gene changes (EGFR or LKB1/STK11 mutations). About 56 adults with advanced disease will receive the combination. The main goal i…

This phase 2 trial is testing whether combining the immunotherapy drug tislelizumab with other experimental drugs, with or without chemotherapy, can shrink tumors and control advanced non-small cell lung cancer. About 400 people who have not had prior treatment for metastatic dis…

This study tests the safety of combining the targeted drug alectinib with chemotherapy in people who have had surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). The 11 participants received up to four cycles of the drug combo after their tumor w…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…

This study tests whether adding a special type of radiation to standard immunotherapy before surgery can help prevent lung cancer from coming back. About 90 people with stage III lung cancer that has spread to lymph nodes will receive chemotherapy, then immunotherapy plus radiati…

This study is testing whether a combination of three drugs—nivolumab, ipilimumab, and nintedanib—can safely shrink tumors in people with advanced non-small cell lung cancer that has no curative options. The trial involves 66 participants and is split into two phases: the first fi…

This phase III trial is testing the immunotherapy drug atezolizumab (Tecentriq) in 60 people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. Participants receive the drug every three weeks. The study aims to see if it helps the…

This study tests whether a shot (subcutaneous injection) of pembrolizumab works as well as the standard IV infusion for people with metastatic non-small cell lung cancer that has high PD-L1 levels. About 67 participants will receive either the shot or IV treatment, and researcher…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study is monitoring the safety and side effects of the drug XALKORI in people with a certain type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. About 97 participants are being followed to see how well the drug works a…

This study was designed to test a new oral drug called IN10018 combined with chemotherapy (nab-paclitaxel) and an immunotherapy (tislelizumab) in people with advanced solid tumors, specifically non-small cell lung cancer, that had stopped responding to prior treatments. The goal …

This study compares a new drug, DS-1062a, to the standard chemotherapy docetaxel in about 600 adults with advanced or metastatic non-small cell lung cancer that has worsened after previous treatment. The goal is to see if DS-1062a can slow cancer growth or extend survival better …

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help control non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if the combinati…

This study was designed to test two immunotherapy drugs, atezolizumab and tiragolumab, in people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. The trial was withdrawn before enrolling any participants, so no results are avail…

This early-stage study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have come back or spread and no longer respond to standard treatments. The main goal is to check the drug's safety and find the…

This Phase 3 study compares a new experimental drug, SHR-A2009, to standard chemotherapy in 498 people with advanced EGFR-mutated non-small cell lung cancer whose current targeted therapy (EGFR TKI) has stopped working. The goal is to see if SHR-A2009 can better control the cance…

This phase 3 study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after surgery helps people with stage II or IIIA non-small cell lung cancer. About 453 participants will receive either tislelizumab plus chemo or a placebo plus chemo,…

This program offers capmatinib, an oral drug, to people with advanced non-small cell lung cancer who have no other treatment options and cannot join a clinical trial. It is a managed access (compassionate use) program, not a formal study. The goal is to provide potential benefit …

This early-phase trial is testing whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer with MET alterations. Only 3 adults with advanced disease that cannot be surgically removed are enrolled. The main goal is to check safety and see…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the v…

This early-stage trial tests an experimental drug called RC148, given as an injection, in people with advanced non-small cell lung cancer that has spread. The study looks at how well the drug shrinks tumors, either alone or combined with other treatments. About 121 adults aged 18…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This phase 1/2 trial tests whether adding difluoromethylornithine (DFMO) to the immunotherapy pembrolizumab (Keytruda) is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change (STK11/LKB1 deficiency). About 45 participants will …

This phase 2 trial tests whether adding the cholesterol-lowering drug alirocumab to standard chemotherapy and immunotherapy (cemiplimab) before surgery helps eliminate more cancer in people with stage 1B-3A non-small cell lung cancer. About 126 participants will be randomly assig…

This phase 2 trial tested a combination of two targeted drugs, tepotinib and osimertinib, in 140 people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and had stopped responding to the standard drug osimertinib. The goal was to see…

This phase 2 trial tests whether adding savolitinib to osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR-mutated, MET-amplified) that has worsened despite osimertinib treatment. About 30 adults will receive either the…

This Phase 3 trial tests whether adding radiation to the standard combination of pembrolizumab (an immunotherapy) and chemotherapy can improve survival in people with advanced non-small cell lung cancer. About 327 participants with stage IIIB/IV disease will receive either the tr…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This early-phase study tests whether a new treatment called KSQ-001EX is safe for people with advanced solid tumors like melanoma, lung cancer, or head and neck cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are genetically modified …

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This early-stage study tests the safety of cemiplimab, a drug that helps the immune system fight cancer, alone or with other drugs in Japanese patients with advanced malignancies, especially lung cancer. About 146 participants will receive different combinations to see if tumors …

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that lacks specific genetic changes. About 193 participants will receive these comb…

This phase 2 trial tests the drug T-DXd (Enhertu) in 27 adults with advanced HER2-mutant lung cancer that has spread to the brain but is not causing symptoms. The main goal is to see how long the drug can keep brain tumors from growing. T-DXd is already approved for certain lung …

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This phase II trial tests a combination of immunotherapy (durvalumab), chemotherapy (carboplatin and paclitaxel), and targeted radiation to metastatic spots, followed by surgery or radiation to the main lung tumor. The goal is to see if this aggressive approach can keep the cance…

This study tests repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, to help current smokers quit and avoid relapse. Researchers are enrolling 206 right-handed smokers who smoke 5-25 cigarettes daily and want to quit within 30 days. Th…

This phase 3 study tests whether the targeted drug abemaciclib can help people with stage IV lung cancer that has a KRAS mutation and has worsened after chemotherapy. About 450 participants received either abemaciclib or another targeted drug (erlotinib), both alongside best supp…

This study tests an experimental drug called AB-106 in 173 adults with advanced non-small cell lung cancer that has a specific genetic change (ROS1 fusion). The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive AB-106 alone, and thei…

This phase II trial tests a three-step approach for stage II or III non-small cell lung cancer. First, the main tumor gets a high-dose radiation blast (SBRT). Then, the chest lymph nodes receive standard radiation plus chemotherapy. Finally, patients get an immunotherapy drug (du…

This study tests whether giving stereotactic body radiotherapy (SBRT) to growing metastatic tumors can delay overall cancer progression. About 107 adults with triple-negative breast cancer or non-small cell lung cancer that has started to grow in a few spots will receive SBRT or …

This study tests whether adding the drug MPDL3280A (a type of immunotherapy) to standard chemotherapy and radiation is safe for people with advanced non-small cell lung cancer that cannot be surgically removed. About 52 participants will receive the combination and be monitored f…

This study tests whether a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has not been treated…

This study tests whether adding a new drug called uliledlimab to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer live longer without their disease getting worse. About 150 adults who have not had prior treatment for their advanced …

This study tests whether a new drug combination (uliledlimab plus toripalimab) works better than the standard immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that hasn't been treated yet. The trial includes 450 participants whose tumors have specif…

This study tests a new daily pill, sunvozertinib (DZD9008), in people with advanced non-small cell lung cancer that has certain genetic mutations (EGFR or HER2) and has worsened after prior treatments. The trial aims to find safe doses and see if the drug can shrink tumors. About…

This study tests a new drug called SKB264, given alone or with other treatments, for people with advanced or spreading non-small cell lung cancer. About 356 adults with certain genetic types of lung cancer will take part. The goal is to see if the drug is safe and shrinks tumors.

This study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…

This phase 2 trial tests a combination of lazertinib (a targeted pill) plus two chemotherapy drugs (pemetrexed and carboplatin) in 87 adults with a specific type of advanced lung cancer (EGFR mutation-positive non-small cell lung cancer) that has stopped responding to lazertinib …

This study tests whether the drug trilaciclib, given before chemotherapy, can prevent bone marrow suppression (low blood cell counts) in people with advanced non-small cell lung cancer. About 40 participants will receive trilaciclib before their platinum-based chemo. The main goa…

This early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…

This study tests whether adding fianlimab to standard immunotherapy (cemiplimab) and chemotherapy improves outcomes for people with advanced non-small cell lung cancer. About 950 participants will receive either the triple combination or the double combination. The goal is to see…

This phase II trial tests whether adding two drugs (amivantamab and bevacizumab) to the targeted therapy lazertinib can shrink tumors in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease progressed on a prior targeted therapy. The main goal is to see ho…

This study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in people with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The goal is to see if this combination can overcome drug resistance and shrink tumors.…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This study tests whether combining two or three drugs can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C). The drugs aim to block cancer growth signals. About 153 adults who have or haven't received prior KRAS-targeting therapy will take part…

This early-stage study tests a new drug called BI 1701963, which blocks a cancer-driving protein called KRAS. It is given alone or with an approved drug, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have not responded to prior chemotherapy. The m…

This Phase 2 trial tests whether adding chemotherapy (carboplatin and pemetrexed) to the targeted drug osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The study enrolls 80 patients w…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This study tests whether combining two drugs, pembrolizumab and vorinostat, can help control advanced non-small cell lung cancer. About 120 adults with stage IV lung cancer will receive either the combination or pembrolizumab alone. The goal is to see if the combination is safe a…

This early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that delivers immune-boosting signals directly into tumors, with the im…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This study offers continued access to the drug lorlatinib for people with a specific type of lung cancer (ALK-positive or ROS1-positive non-small cell lung cancer) who are already benefiting from it in earlier Pfizer studies. The main goal is to track long-term safety and side ef…

This study tests an experimental oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma, a type of brain cancer. The drug is designed to block specific EGFR mutations that help these cancers grow. The trial has two p…

This study tests a pill called sunvozertinib given before surgery to people with a certain type of lung cancer (stage II-IIIB non-small cell lung cancer with EGFR exon 20 insertion mutations). The goal is to see if the drug can shrink tumors and improve surgical outcomes. About 2…

This study tested giving the immunotherapy drugs nivolumab (with or without ipilimumab) before surgery to people with a type of lung cancer called non-small-cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were…

This phase 2 study tests whether combining the immunotherapy drug durvalumab with radiation therapy (without chemotherapy) can delay cancer worsening in people with locally advanced non-small cell lung cancer. About 61 participants will receive radiation plus durvalumab infusions…

This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…

This phase 2 study tests whether adding chemotherapy to the targeted drug brigatinib helps people with advanced ALK-positive non-small cell lung cancer live longer without their cancer growing. About 110 people who have not had treatment for advanced disease will receive either b…

This phase 2 study tests two targeted drugs, encorafenib and binimetinib, in 119 people with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the combination can shrink tumors and keep them from growing. Participants take the pill…

This study tests whether adding thymosin alpha 1 to standard chemoradiation and immunotherapy helps patients with advanced non-small cell lung cancer complete a full year of immunotherapy. About 114 adults will participate. The goal is to see if this approach improves survival an…

This study tests whether a new drug called QL1706, combined with chemotherapy, works better than another drug (tislelizumab) plus chemo for people with advanced non-small cell lung cancer that lacks the PD-L1 protein. About 606 adults aged 18-75 are taking part. The goal is to se…

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard two-drug chemotherapy (paclitaxel and bevacizumab) can help people with advanced non-squamous lung cancer whose disease has worsened after prior immunotherapy and chemotherapy. About 156 participan…

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This study tests an experimental drug, telisotuzumab vedotin, in adults with a certain type of advanced lung cancer (c-Met+ non-small cell lung cancer) that has already been treated. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that have …

This study tests an experimental drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds the safest dose, …

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations, chosen based on the unique markers (biomarkers) in each person's tumor. The goal is …

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage III lung cancer that cannot be removed by surgery. About 328 participants will receive either durvalumab or a placebo alongside their chemo …

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study tests a drug called selpercatinib against standard chemotherapy for people with a certain type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). The goal is to see if selpercatinib can delay cancer growth better than current treatments. About 26…

This study tests whether adding hydroxychloroquine (a malaria drug) to the targeted cancer pill erlotinib can delay drug resistance in people with advanced EGFR-mutant non-small cell lung cancer. About 76 participants will receive either erlotinib alone or erlotinib plus hydroxyc…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This phase 3 trial tests whether a new drug called ensartinib works better than the current standard crizotinib for people with ALK-positive non-small cell lung cancer. About 290 participants who have had up to one prior chemotherapy but no prior ALK inhibitor are randomly assign…

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer worsening. About 587 adults with newly diagnosed or recurrent advanced lung cancer will be …

This study tests whether injecting a patient's own blood into the chest tube can stop prolonged air leaks after lung cancer surgery. About 60 adults who still have an air leak three days after surgery will receive the blood patch. Researchers will check if it reduces hospital sta…

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This early-phase trial tests an experimental drug called BL-M02D1 in 14 people with advanced non-small cell lung cancer that has not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. It is too soon to know if it will wor…

This study tests a new drug (SI-B001) combined with a standard pill (osimertinib) in people with advanced non-small cell lung cancer that has stopped responding to previous therapies. About 14 adults will receive the combination to see if it can shrink tumors and control the dise…

This early-stage trial is testing a new drug called HBI-2438 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves throu…

This study tests a new drug called SI-B001 combined with chemotherapy in 69 adults with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Participants must have a specif…

This early-stage trial tests a new oral drug called HBI-2376 in about 42 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS or EGFR mutations and have stopped responding to standard treatments. The main goals are to find a safe dose and unde…

This early-phase trial is testing an experimental drug called BI-1910, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (including lung and liver cancers) that have worsened after standard treatments. The main goals are to see if the drug is saf…

This Phase II study tests a new drug called BL-B01D1, given alone or with the tablet osimertinib, in 198 adults with advanced non-small cell lung cancer. The goal is to see if the treatment shrinks tumors and to check for side effects. Participants must have a confirmed diagnosis…

This early-phase trial tests a combination of a modified virus (VSV-IFNβ-NIS) and immunotherapy drugs (pembrolizumab or ipilimumab+nivolumab) in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine carcinoma, and renal cell carcinoma. The virus …

This trial tests whether giving a higher radiation dose to the most active parts of a lung tumor can better control the cancer. About 78 people with locally advanced non-small cell lung cancer will receive either standard chemoradiation or chemoradiation with an extra radiation b…

This phase 1 trial tests a precise, high-dose radiation technique called SBRT for patients with non-small cell lung cancer whose tumors are located in the ultra-central part of the chest, near the windpipe and major blood vessels. The study enrolls 30 participants to find the hig…

This French phase 3 trial compares pembrolizumab alone versus pembrolizumab plus chemotherapy as a first treatment for advanced non-small-cell lung cancer with high PDL1 levels (50% or more). About 349 participants are enrolled. The goal is to see if the combination reduces early…

This phase II trial tests a precise type of radiation called SABR in 39 people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). The goal is to see if this treatment can control the cancer while keeping side effects manageable. P…

This study tests whether adding precise radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with non-small cell lung cancer. Participants have brain tumors that remain after 3-6 months of a targeted drug. The goal is to see…

This early-phase trial tests an experimental drug called AB248, which aims to boost the body's cancer-fighting immune cells. It is given alone or with the approved immunotherapy Keytruda to adults with advanced solid tumors like lung cancer, melanoma, or kidney cancer. The main g…

This study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…

This study looks at whether fluid washed from inside a lung tumor can be used to find genetic changes in early-stage lung cancer. About 50 adults with suspected resectable lung cancer will have a special bronchoscopy to collect this fluid. The goal is to see if this method is as …

This study looks at a new lab technique called OSNA that may find tiny amounts of cancer in lymph nodes better than current methods. About 130 people with early-stage lung cancer having robotic surgery will take part. Half will have their lymph nodes checked with OSNA, the other …

This study tests whether a liquid biopsy (a blood test that looks for cancer DNA) can help doctors decide on treatment for advanced lung cancer faster than the usual method of testing tumor tissue. About 170 newly diagnosed patients will receive both the blood test and standard t…

This study was designed to test whether an oral drug called SPI-1005 could prevent hearing loss and ringing in the ears caused by platinum-based chemotherapy. It was planned for adults with advanced lung or head and neck cancer. The study was withdrawn before enrolling any partic…

This study tested a shorter course of high-dose radiation for people with stage IV lung cancer. The goal was to see if giving fewer, larger doses over fewer days could be as safe and effective as the standard longer schedule. 37 participants received radiation every other day for…

This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study tests whether a few counseling sessions can improve quality of life for adults who have just finished lung cancer treatment with the goal of cure. One group gets five sessions focused on coping skills and social support; the other gets one session with referrals. Resea…

This study tests a new support program for adults with lung cancer or mesothelioma who have finished treatment. The goal is to help them improve their quality of life as they move from active treatment to regular check-ups. About 21 participants will try the program to see if it …

This study tests whether a progressive exercise program can reduce chronic pain in veteran lung cancer survivors aged 60-80. Nine participants will do treadmill walking, resistance bands, and balance exercises. The goal is to see if exercise can be a safe alternative to opioids f…

This study tests whether adding acupuncture to standard immunotherapy and chemotherapy helps people with advanced non-small cell lung cancer. Sixty participants will receive either real or sham acupuncture alongside their first four treatment cycles. The goal is to see if acupunc…

This study looks at how tiny genetic differences (called SNPs) in ALK-positive non-small cell lung cancer patients might influence how well the drug alectinib works and what side effects occur. Researchers will analyze DNA from 600 patients who have been taking alectinib for at l…

This study follows 305 people with stage III non-small cell lung cancer who have specific genetic mutations. Researchers regularly test their blood for tiny traces of cancer DNA (minimal residual disease, or MRD) to see if it can predict when the cancer will come back. The goal i…

This study looks at how doctors in Russia treat advanced or metastatic non-small-cell lung cancer in everyday practice. Researchers will follow about 1500 adults across 20 cancer centers to see which treatments and genetic tests are used. The goal is to understand real-world care…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study looks at how doctors currently diagnose lung and breast cancer using tissue samples. It will also test whether artificial intelligence (AI) can help analyze these samples faster and more accurately. Researchers will review records from 600 patients to measure diagnosis…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study collects and analyzes lung cancer tissue samples from 500 patients in Asia to find out which genetic changes are most common. The goal is to better understand the disease in the local population. Participants must have a tissue sample available and be healthy enough fo…

This study follows 814 people with early-stage non-small cell lung cancer to understand how the cancer evolves and spreads. Researchers collect tumor samples and medical data to see how genetic changes relate to treatment outcomes. The goal is to find ways to reduce the chance of…

This study looks at circulating tumor cells (CTCs) in the blood of 80 people with advanced lung cancer. Researchers will grow these cells in the lab to test new drugs that target DNA repair. The goal is to learn how to personalize treatment based on each person's tumor cell featu…

This study asks 50 lung cancer doctors to review AI-generated explanations for patient prognosis and rate how trustworthy they seem. The goal is to see if a newer type of AI (neurosymbolic) is more trusted than standard methods. No patients are treated; the data is simulated. The…

This study follows 446 people with stage I non-small cell lung cancer who chose either surgery or stereotactic body radiation therapy (SBRT). Researchers will track cancer recurrence, survival, and quality of life for up to 3 years to see which treatment offers better outcomes. T…

This study aims to collect medical history and tissue or saliva samples from 100 people with a specific type of advanced lung cancer called ALK+ non-small cell lung cancer. Researchers will analyze these samples to better understand the genetic and immune features of the disease.…

This pilot study is looking at whether dental erosion (loss of tooth enamel) could be a non-invasive biomarker for esophagogastric cancer and other cancers. Researchers will survey 174 participants (cancer patients and healthy volunteers) about diet, habits, and GERD symptoms, an…

This study looks at whether PET-CT scans can predict if non-small cell lung cancer has spread to nearby lymph nodes. Researchers will compare two types of PET-CT scans (using different tracers) with the actual results from surgery. The goal is to see if these scans can help docto…

This study looks at the bacteria living in the gut, lungs, and airways of 40 people with non-small cell lung cancer. Half receive surgery only, and half get chemotherapy before surgery. Researchers collect samples like blood, saliva, stool, and lung tissue to see how these bacter…

This study looks at how the heart works during a 6-minute walk test in people with advanced lung cancer who are getting chemotherapy, radiation, and immunotherapy. The goal is to see if heart measurements can help predict side effects and how well patients do over time. About 231…

This early study tests whether using real-time MRI to guide radiation therapy is possible for people with advanced non-small cell lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 adults with stage III lung c…

This study looks at whether computer analysis of PET/CT scans can help doctors more accurately stage non-small cell lung cancer and predict genetic mutations. Researchers will use data from 500 patients to build and test machine learning models. The goal is to provide better, per…

This study tests whether a team of specialists (Molecular Tumor Board) can help choose better treatments for people with advanced lung cancer compared to usual care. About 659 participants with stage IIb-IV non-small cell lung cancer will be followed to see if the expert approach…

This study looks at patients with non-small-cell lung cancer that has spread only to the brain (fewer than 5 spots). Researchers will review different treatment strategies used at two hospitals to see which leads to longer survival without the disease getting worse. The goal is t…

This study tests a new technology that adjusts the radiation beam in real time to follow lung tumors as they move with breathing. About 20 adults with early-stage lung cancer or limited lung metastases will receive standard radiotherapy with this tracking system. The main goal is…

This study looks at whether a computer model can analyze routine brain MRI scans to predict if a lung cancer that has spread to the brain has certain genetic changes (EGFR or ALK). The goal is to see if this noninvasive method can replace the need for a brain tumor biopsy to guid…

This study gives the immunotherapy drug durvalumab to people with operable non-small cell lung cancer before their surgery. The main goal is to see how the drug changes the tumor and immune system, not to cure the disease. About 25 adults with stage IIA to IIIB lung cancer will t…

This study looks at the best way to collect tissue samples from lung cancer patients using a thin tube passed through the mouth (endobronchial ultrasound). It compares taking 2 versus 3 samples from each lymph node to see if fewer samples still provide enough material for genetic…

This study looks at two methods for keeping the lungs still during radiation treatment for lung cancer. One method uses a special camera system (SGRT) alone, and the other adds small implanted markers (fiducials) for extra guidance. The goal is to see which approach is more relia…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab…

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This study observes how the drug osimertinib works in real-life settings for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 274 adults in France will be followed for up to 3 years to see how long they live, how their disease changes, an…

This study tests whether a remote monitoring system—including a smartphone app, a Fitbit, and a smart pill cap—can effectively track symptoms and side effects in 30 lung cancer patients taking oral targeted therapy. Participants will use the system for up to 24 weeks, and the goa…

This study is testing whether a blood test that looks for tumor DNA can help doctors decide when to safely stop immunotherapy in people with advanced melanoma or non-small cell lung cancer. About 39 patients who have been on immunotherapy for at least a year and show no signs of …

This study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit fr…

This early-stage study tests whether a dye called indocyanine green, injected near a lung tumor during surgery, can help surgeons see and remove the first lymph node that drains from the cancer. The goal is to improve detection of cancer spread and guide more precise treatment. T…

This study is looking at whether changes in a blood test called tumor fraction can help predict how well immunotherapy works in people with non-small cell lung cancer or kidney cancer. About 100 adults will have blood samples taken before and during their standard treatment. The …

This study tracks 221 people with stage II or III lung cancer to see how chemoradiation therapy affects their heart health. Participants undergo heart scans, blood tests, and quality-of-life surveys before, during, and for at least two years after treatment. The goal is to better…

This observational study tracks over 5,000 people with non-small cell lung cancer to see how doctors use the VeriStrat blood test when deciding on treatment. Researchers want to learn if the test results change what therapy patients receive and whether new experimental tests can …

This study compares two types of minimally invasive lung cancer surgery: robotic-assisted surgery and video-assisted thoracoscopic surgery (VATS). About 446 people with early-stage non-small cell lung cancer will be randomly assigned to one of the two procedures. The main goal is…